Submitted by reuters8361 in health
Eli Lilly's <a href="https://www.reuters.com/markets/companies/LLY.N" target="_blank">(LLY.N)</a> diabetes drug Mounjaro has gained the backing of Britain's healthcare cost-effectiveness watchdog, which said it would be a good option for patients with poorly …